舆论监督越给力 药品监管越有力

2019-02-14 佚名 中国医药报

春节前夕,“010-83025701”这个新闻热线号码悄然登上《中国医药报》社全媒体平台,打开报纸、登录网页、点开微信,都能看到它。一头连着编辑部,一头连着老百姓,通过这条热线,《中国医药报》社将广泛征集新闻线索,强化舆论监督。正值深入贯彻落实习近平总书记在中共中央政治局第十二次集体学习时的重要讲话精神之际,这是《中国医药报》社贯彻落实讲话精神以及习近平总书记关于新闻舆论工作系列重要论述的一个具体

春节前夕,“010-83025701”这个新闻热线号码悄然登上《中国医药报》社全媒体平台,打开报纸、登录网页、点开微信,都能看到它。一头连着编辑部,一头连着老百姓,通过这条热线,《中国医药报》社将广泛征集新闻线索,强化舆论监督。正值深入贯彻落实习近平总书记在中共中央政治局第十二次集体学习时的重要讲话精神之际,这是《中国医药报》社贯彻落实讲话精神以及习近平总书记关于新闻舆论工作系列重要论述的一个具体举措。

舆论监督是党赋予媒体的职责使命。重视舆论监督是马克思主义政党的优良传统。党的十八大以来,以习近平同志为核心的党中央对舆论监督工作的认识更加全面、判断更加深刻、把握更加有力。2016年2月19日,习近平总书记在党的新闻舆论工作座谈会上明确指出:“舆论监督和正面宣传是统一的。新闻媒体要直面工作中存在的问题,直面社会丑恶现象,激浊扬清、针砭时弊。”这为我们在新形势下做好党的舆

论监督工作确立了重要遵循和行动指南。党的十九大报告指出:“构建党统一指挥、全面覆盖、权威高效的监督体系,把党内监督同国家机关监督、民主监督、司法监督、群众监督、舆论监督贯通起来,增强监督合力。”舆论监督成为党和国家监督体系的重要组成部分。这意味着,新闻媒体要从坚持党管媒体、全面从严治党的高度认识舆论监督,做到服从服务于党和国家大局不错位、党和人民需要时不缺位。

舆论监督是媒体面临的重大时代课题。时者,势也。在“全程媒体、全息媒体、全员媒体、全效媒体”的全媒体时代,“人人都有麦克风,人人都是通讯社”。主流媒体的话语权和传统概念上的舆论监督都面临新的挑战——你不监督,自有别人来监督。很多热点事件,都是自媒体首发,引起舆论关注,主流媒体随之跟进。1月25日,习近平总书记在中共中央政治局第十二次集体学习时强调要打造新型传播平台,扩大主流价值影响力版图。在信息芜杂、人声鼎沸的背景下,主流媒体要扩大影响力版图,就必须牢牢把握舆论引导和舆论监督的“一体两面”,

坚持正面宣传为主,敢于开展舆论监督,否则就会把舆论监督职能“拱手相让”,丧失舆论场主动权和主导权。作为医药行业主流媒体,《中国医药报》社必须旗帜鲜明地加强舆论监督,站稳药品监管系统宣传主阵地。这是我们的责任,也是我们的担当。

舆论监督是提升药品安全治理效能的利器。1月31日《人民日报》刊登的评论《以传播优势提升治理效能》指出,媒体融合不只是一个传播命题,同样也是一个治理命题。顺应媒体融合发展大势,对提高社会治理的社会化、法治化、智能化、专业化水平大有裨益。把视线转向药品安全治理领域,当前,我国医药产业的整体水平离高质量发展还有明显差距,安全风险多发易发,监管实践中还存在有法不依、执法不严现象。作为落实“四个最严”的重要抓手和依法监管的有效途径,舆论监督可以提升监管效能,可以促进行业自律,可以回应社会关切,可以维护公众权益。媒体融合形势下,公众与媒体的良性互动增强,媒体通过舆论走势可以精准制定并及时调整监督策略,靶向发力,向影响用药

安全的潜规则和不法行为“亮剑”。激浊方能扬清,扶正必须祛邪,这既有助于净化药品市场,维护百姓知情权和安全用药权益,也为监管工作“鸣锣开道”,营造了良好氛围。

2019年新年伊始,《中国医药报》社针对国家药品监管局发布的化妆品宣称“药妆”“含有EGF”均属违法行为的相关问题解答,曝光一些电商平台以及化妆品涉及“药妆”的违法行为。在舆论影响下,京东、淘宝、苏宁易购等电商平台纷纷掀起“药妆”下架潮。一场净化化妆品市场的战斗取得阶段性成果。实践证明,媒体不仅是药品监管信息的传播者,还是药品监管工作的参与者,可以发挥扬声器和助推器作用,甚至达到“不战而屈人之兵”的效果。针对标示某染发剂企业的产品一年之内连续十多次登上化妆品抽检不合格榜的情况,《中国医药报》社旗下报纸、网站、微信公众号和“今日头条”头条号等媒体平台集中报道、梯次传播,进行舆论监督。舆论监督是个技术活儿,融媒体手段在药品安全舆论监督中的运用,是“互联网+”在监管中的实际应用范例之一。只要运用得当,

就能让互联网这个最大变量,成为药品监管事业发展的最大增量!

唱赞歌易,讲问题难。习近平总书记强调,发表批评性报道要事实准确、分析客观。舆论监督的初心是发现问题、促进解决。媒体不能做宣泄情绪的“键盘侠”,而要做针砭时弊的“啄木鸟”。因此,我们将坚持正确的舆论导向,坚持报道的真实、客观、准确,坚守维护社会公平正义的责任感和新闻职业操守,创造经得起挑刺和质疑,经得起历史、实践和人民检验的监督性报道。我们欢迎广大读者来监督我们的监督性报道。

乐闻过,罔不兴;拒谏,罔不乱。在习近平总书记关于新闻舆论工作重要论述的引领下,各地纷纷吹响加强舆论监督、鼓励舆论监督的号角。山东、海南等地释放出“求监督”的积极信号。北京市则将媒体监督纳入“月考”,要求凡曝光的问题都要闻风而动。我们也希望在药品监管系统能看到更多“闻过则喜”的态度,更多“闻过则改”的行动,因为——

舆论监督越给力,药品监管越有力!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754636, encodeId=05c41e546366b, content=<a href='/topic/show?id=f1cf86534fa' target=_blank style='color:#2F92EE;'>#舆论#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86534, encryptionId=f1cf86534fa, topicName=舆论)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e0536772516, createdName=steven_u14, createdTime=Sat May 18 22:35:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672238, encodeId=c1b716e22382e, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Mar 13 06:35:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683950, encodeId=7962168395020, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Apr 12 21:35:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371602, encodeId=f85113e1602fc, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sat Feb 16 02:35:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-05-18 steven_u14
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754636, encodeId=05c41e546366b, content=<a href='/topic/show?id=f1cf86534fa' target=_blank style='color:#2F92EE;'>#舆论#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86534, encryptionId=f1cf86534fa, topicName=舆论)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e0536772516, createdName=steven_u14, createdTime=Sat May 18 22:35:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672238, encodeId=c1b716e22382e, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Mar 13 06:35:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683950, encodeId=7962168395020, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Apr 12 21:35:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371602, encodeId=f85113e1602fc, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sat Feb 16 02:35:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754636, encodeId=05c41e546366b, content=<a href='/topic/show?id=f1cf86534fa' target=_blank style='color:#2F92EE;'>#舆论#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86534, encryptionId=f1cf86534fa, topicName=舆论)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e0536772516, createdName=steven_u14, createdTime=Sat May 18 22:35:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672238, encodeId=c1b716e22382e, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Mar 13 06:35:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683950, encodeId=7962168395020, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Apr 12 21:35:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371602, encodeId=f85113e1602fc, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sat Feb 16 02:35:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-04-12 zxl738
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754636, encodeId=05c41e546366b, content=<a href='/topic/show?id=f1cf86534fa' target=_blank style='color:#2F92EE;'>#舆论#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86534, encryptionId=f1cf86534fa, topicName=舆论)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e0536772516, createdName=steven_u14, createdTime=Sat May 18 22:35:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672238, encodeId=c1b716e22382e, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Wed Mar 13 06:35:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683950, encodeId=7962168395020, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Apr 12 21:35:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371602, encodeId=f85113e1602fc, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Sat Feb 16 02:35:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 wwzzly